Printer Friendly

Progen's Anti-cancer Drug Trial Receives Second Site Approval From Peter MacCallum Cancer Institute, Subject to Final Administrative Filings.

BRISBANE, Australia--(BW HealthWire)--Aug. 26, 1999--

Progen Industries Limited (ASX:PGL)(NASDAQ:PGLAF), today received provisional approval from the Peter MacCallum Cancer Institute's Ethics Committee to commence testing its anti-cancer drug, PI-88, at the Institute under the umbrella of Centre for Developmental Cancer Therapeutics.

Progen Industries Limited Managing Director Mr Alan Scott said this was the second CDCT location in Melbourne at which the biotechnology company had received approval to hold the trial.

"In June this year, we received provisional approval from the Royal Melbourne Hospital's Ethics Committee to trial PI-88 at the Hospital under the CDCT," he said.

He said the trial would take place in Melbourne between the two locations and would involve approximately 40 patients whose tumours no longer responded to standard therapies."

He said the CDCT was an important partner in the development of PI-88.

The CDCT is a consortium involving four major Melbourne hospitals and two internationally renowned oncology research centres. This network offers the facilities and expertise for conducting Phase I and Phase II clinical trials.

A CDCT spokesperson said the organisation was working closely with Progen to get the trial up and running and, subject to further administrative procedures, it was confident they could begin in the near future. Progen therefore, subject to this factor, is planning for the trial to start in September.

If this trial is successful, Progen will move PI-88 to a Phase II trial which involves testing a fixed dose of the drug on an increased number of cancer patients to assess its efficacy.

Mr Scott said PI-88 had the potential to treat a wide range of cancers including breast, lung, prostate and colon cancer.

"The incidence of cancer throughout the world is growing at an accelerated rate with Australia alone experiencing an increase of eight percent for men and 11 percent for women between 1985 and 1995," he said.

"Current data suggests that between one in three to four Australians will suffer from cancer during their lifetime."(a)

Mr Scott said the world cancer therapeutic market was estimated to be currently worth A$20 billion.(b)

Progen is expected to announce its full year results shortly. As at August 25, 1999, Progen's market capitalisation totalled A$87 million.

Note (a): Australian Institute of Health and Welfare

Note (b): Frost and Sullivan market Intelligence, 1993

This press release contains forward-looking statements that are based on current management expectations. These statements may differ materially from actual future events or results as a result of certain risks and uncertainties, including but not limited to, risks associated with the development and manufacture of PI-88 and inherent in the extensive regulatory approval process mandated by the Australian Therapeutic Goods Administration and the United States Food and Drug Administration, delays in the conduct of clinical trials, in obtaining the necessary approvals for additional clinical testing and for marketing of PI-88, market acceptance of the compound, general economic conditions, and other risks and uncertainties detailed from time to time in Progen's filings with the Australian Stock Exchange and the United States Securities and Exchange Commission.
COPYRIGHT 1999 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1999, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Aug 26, 1999
Words:511
Previous Article:bamboo.com, Inc. Announces Initial Public Offering.
Next Article:SAP Venture Fund Europe Invests in Heiler Software.
Topics:


Related Articles
Chemotherapy combo boosts survival.
Progen Commences First Trial of Its PI-88 Drug On Cancer Patients.
New Carbohydrate Based Angiogenesis Inhibitor Shown To Retard Cancer Presented At Annual Meeting of American Association for Cancer Research.
New Cardiovascular Application From Cancer Drug Found by Progen Industries.
Two New Studies Launched To Test One Compound Aimed At Both Cancer and Cardiovascular Disease.
Progen Clears First Clinical Trial Hurdle With Conclusion of PI-88 Phase Ib Trial in Cancer Patients.
PROGEN'S FIRST U.S. CLINICAL TRIAL WITH PI-88 BEGINS.
GPC BIOTECH GETS U.S. PATENT FOR ANTI-CANCER CELL INHIBITOR.
GPC BIOTECH PRESENTS NEW SATRAPLATIN DATA AT AACR.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters